OBGYN Questions: Difference between revisions
Vincent Chan (talk | contribs) No edit summary |
Vincent Chan (talk | contribs) No edit summary |
||
| Line 367: | Line 367: | ||
+the management is the same for pregnant and non-pregnant patients | +the management is the same for pregnant and non-pregnant patients | ||
||acetaminophen readily crosses the placenta, which places the fetus at risk for hepatotoxicity. However, NAPQI does not cross the placenta, and thus, the fetus must metabolize the acetaminophen for toxicity to occur. The fetus is able to start metabolizing acetaminophen into toxic and non-toxic metabolites at approximately 18 weeks of gestational age. NAC does cross the placenta and its use is indicated in pregnant women whose serum concentration is above the treatment line of the Rumack-Matthew nomogram. Fetal outcome appears to be worse with delays in commencing NAC. | ||acetaminophen readily crosses the placenta, which places the fetus at risk for hepatotoxicity. However, NAPQI does not cross the placenta, and thus, the fetus must metabolize the acetaminophen for toxicity to occur. The fetus is able to start metabolizing acetaminophen into toxic and non-toxic metabolites at approximately 18 weeks of gestational age. NAC does cross the placenta and its use is indicated in pregnant women whose serum concentration is above the treatment line of the Rumack-Matthew nomogram. Fetal outcome appears to be worse with delays in commencing NAC. | ||
{Your patient with an ectopic pregnancy wants to know if she is a candidate for non-surgical treatment (methotrexate). Which of the following statements about methotrexate for ectopic pregnancy is true? | {Your patient with an ectopic pregnancy wants to know if she is a candidate for non-surgical treatment (methotrexate). Which of the following statements about methotrexate for ectopic pregnancy is true? | ||
|type="[]"} | |type="[]"} | ||
Revision as of 21:52, 25 November 2013
